VBY-891
/ LEO Pharma, Virobay
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 31, 2014
TPG-backed biotech Virobay withdraws $50 million IPO
(Nasdaq)
- "Virobay...withdrew its plans for an initial public offering on Friday. The company originally planned to raise $50 million during the week of October 13....Virobay has completed Phase 1 trials for treatments that target neuropathic pain, Crohn's disease, and psoriasis, all of which are expected to begin Phase 2 trials in 2015."
Anticipated new P2 trial • Commercial • Inflammatory Bowel Disease • Pain • Psoriasis
1 to 1
Of
1
Go to page
1